WHO Drug Information, Vol. 26, No. 3, 2012                                                Recommended INN: List 68



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 68
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List
No. 14, 2011 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 68
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans
la Liste récapitulative No. 14, 2011 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 68
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran
reunidas en Cumulative List No. 14, 2011 (disponible sólo en CD-ROM).


                                                                                                                 301
Recommended INN: List 68                                                                 WHO Drug Information, Vol. 26, No. 3, 2012




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 acidum deoxycholicum
 deoxycholic acid                          3α,12α-dihydroxy-5β-cholan-24-oic acid

 acide désoxycholique                      acide 3α,12α-dihydroxy-5β-cholan-24-oïque

 ácido desoxicólico                        ácido 3α,12α-dihidroxi-5β-colan-24-oico

                                           C24H40O4
                                                                        H3C           H
                                                                      OH
                                                                  H     CH3                    CO2H
                                                                                         H
                                                         CH3          H

                                                                  H            H
                                            H
                                            HO           H


                               18
 acidum florilglutamicum ( F)
                      18                                     18
 florilglutamic acid ( F)                  (4S)-4-(3-[ F]fluoropropyl)-L-glutamic acid
                        18                                                18
 acide florilglutamique ( F)               acide (4S)-4-(3-[ F]fluoropropyl)-L-glutamique
                       18                                                 18
 ácido florilglútamico ( F)                ácido (4S)-4-(3-[ F]fluoropropil)-L-glutámico
                                                    18
                                           C8H14 FNO4

                                                     HO2C                           CO2H

                                                                      H H          NH2
                                            [18F]



 acidum tiazoticum
 tiazotic acid                             [(5-methyl-1H-1,2,4-triazol-3-yl)sulfanyl]acetic acid

 acide tiazotique                          acide [(5-méthyl-1H-1,2,4-triazol-3-yl)sulfanyl]acétique

 ácido tiazótico                           ácido [(5-metil-1H-1,2,4-triazol-3-il)sulfanil]acético

                                           C5H7N3O2S

                                                    HN       N
                                                                                   CO2H
                                            H3C          N            S




302
WHO Drug Information, Vol. 26, No. 3, 2012                                                   Recommended INN: List 68


 amitifadinum
 amitifadine                                 (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane

 amitifadine                                 (1R,5S)-1-(3,4-dichlorophényl)-3-azabicyclo[3.1.0]hexane

 amitifadina                                 (1R,5S)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0]hexano

                                             C11H11Cl2N
                                                              H
                                                              N


                                                                   H

                                             Cl
                                                     Cl

 bamosiranum
 bamosiran                                   siRNA inhibitor of β2-adrenergic receptor production;
                                             RNA duplex of cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-
                                             uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-
                                             cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-
                                             uridylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-
                                             cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-
                                             thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl-
                                             (5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-
                                             (5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-
                                             (5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-
                                             (5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-
                                             (5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidine

 bamosiran                                   petit ARN interférant (siRNA) inhibiteur de la production du récepteur
                                             adrénergique β2;
                                             duplex ARN du brin cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-
                                             (3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-
                                             (3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-
                                             (3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-
                                             (3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-
                                             (3'→5')-thymidylyl-(3'→5')-thymidine avec le brin anti-sens
                                             thymidylyl-(5'→3')-thymidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-
                                             (5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-
                                             (5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-
                                             (5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-
                                             (5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-
                                             (5'→3')-cytidine

 bamosirán                                   ARN interferente pequeño (siRNA) inhibidor de la producción del
                                             receptor adrenérgico β2
                                             ARN dúplex de la cadena citidilil-(3'→5')-adenilil-(3'→5')-uridilil-
                                             (3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-
                                             citidilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-
                                             (3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-
                                             citidilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-timidilil-(3'→5')-
                                             timidina con la cadena antisentido timidilil-(5'→3')-timidilil-(5'→3')-
                                             guanilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-citidilil-
                                             (5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-
                                             adenilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-uridilil-
                                             (5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-
                                             (5'→3')-citidina
                                             C401H500N150O290P40
                                                      (3'-5')CAUUGUGCAUGUGAUCCAG-dT-dT
                                             (5'-3')dT-dT-GUAACACGUACACUAGGUC

                                                                                                                          303
Recommended INN: List 68                               WHO Drug Information, Vol. 26, No. 3, 2012




 brexpiprazolum
 brexpiprazole             7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-
                           2(1H)-one

 brexpiprazole             7-{4-[4-(1-benzothiophén-4-yl)pipérazin-1-yl]butoxy}quinoléin-
                           2(1H)-one

 brexpiprazol              7-{4-[4-(1-benzotiofen-4-il)piperazin-1-il]butoxi}quinolin-2(1H)-ona

                           C25H27N3O2S

                                                                           H
                                                                 O         N     O
                                                   N
                           S               N




 buparlisibum
 buparlisib                5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-
                           2-amine

 buparlisib                5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluorométhyl)pyridin-
                           2-amine

 buparlisib                5-[2,6-bis(morfolin-4-il)pirimidin-4-il]-4-(trifluorometil)piridin-2-amina

                           C18H21F3N6O2

                                           O


                                           N

                                       N       N

                                  N                    N
                           O
                                           F3C             NH2

 camicinalum
 camicinal                 1-{4-[(3-fluorophenyl)amino]piperidin-1-yl}-2-(4-{[(3S)-3-
                           methylpiperazin-1-yl]methyl}phenyl)ethan-1-one

 camicinal                 1-{4-[(3-fluorophényl)amino]pipéridin-1-yl}-2-(4-{[(3S)-3-
                           méthylpipérazin-1-yl]méthyl}phényl)éthan-1-one

 camicinal                 1-{4-[(3-fluorofenil)amino]piperidin-1-il}-2-(4-{[(3S)-3-metilpiperazin-
                           1-il]metil}fenil)etan-1-ona

                           C25H33FN4O

                                   N                   O                  F
                           HN
                                                            N
                               H CH3
                                                                     N
                                                                     H




304
WHO Drug Information, Vol. 26, No. 3, 2012                                                            Recommended INN: List 68


 caplacizumabum #
 caplacizumab                                immunoglobulin VH-linker-VH fragment, anti-[Homo sapiens VWF
                                             (von Willebrand factor) A1 domain], humanized monoclonal
                                             antibody;
                                             VH-linker-VH chain (1-259) [humanized VH (Homo sapiens IGHV3-
                                             23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] -
                                             trialanyl linker (129-131) -[humanized VH (Homo sapiens IGHV3-
                                             23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)

 caplacizumab                                immunoglobuline fragment VH-linker-VH, anti-[Homo sapiens VWF
                                             (facteur de von Willebrand) domaine A1], anticorps monoclonal
                                             humanisé;
                                             chaîne VH-linker-VH (1-259) [VH humanisé (Homo sapiens IGHV3-
                                             23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] -
                                             trialanyl linker (129-131) -[VH humanisé (Homo sapiens IGHV3-
                                             23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)

 caplacizumab                                inmunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de
                                             von Willebrand) de Homo sapiens dominio A1], anticuerpo
                                             monoclonal humanizado;
                                             cadena VH-conector-VH (1-259) [VH humanizado (Homo sapiens
                                             IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-
                                             128)] -trialanil conector (129-131) -[VH humanizado (Homo sapiens
                                             IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21]
                                             (132-259)

                                             EVQLVESGGG      LVQPGGSLRL       SCAASGRTFS       YNPMGWFRQA       PGKGRELVAA        50
                                             ISRTGGSTYY      PDSVEGRFTI       SRDNAKRMVY       LQMNSLRAED       TAVYYCAAAG       100
                                             VRAEDGRVRT      LPSEYTFWGQ       GTQVTVSSAA       AEVQLVESGG       GLVQPGGSLR       150
                                             LSCAASGRTF      SYNPMGWFRQ       APGKGRELVA       AISRTGGSTY       YPDSVEGRFT       200
                                             ISRDNAKRMV      YLQMNSLRAE       DTAVYYCAAA       GVRAEDGRVR       TLPSEYTFWG       250
                                             QGTQVTVSS                                                                           259

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-chain 22-96 153-227



 cerlapirdinum
 cerlapirdine                                N,N-dimethyl-3-{[3-(naphthalene-1-sulfonyl)-1H-indazol-
                                             5-yl]oxy}propan-1-amine

 cerlapirdine                                N,N-diméthyl-3-{[3-(naphtaléne-1-sulfonyl)-1H-indazol-
                                             5-yl]oxy}propan-1-amine

 cerlapirdina                                N,N-dimetil-3-{[3-(naftaleno-1-sulfonil)-1H-indazol-5-il]oxi}propan-
                                             1-amina

                                             C22H23N3O3S
                                                                                     H
                                                                                     N
                                                                                         N
                                             H3C
                                                    N               O
                                                    CH3                               S
                                                                                 O
                                                                                     O




 dexmecamylaminum
 dexmecamylamine                             (1R,2S,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine

 dexmécamylamine                             (1R,2S,4S)-N,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine

 dexmecamilamina                             (1R,2S,4S)-N,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina


                                                                                                                                        305
Recommended INN: List 68                                              WHO Drug Information, Vol. 26, No. 3, 2012




                                          C11H21N
                                             H
                                                 HN CH3
                                                   CH3
                                                   CH3
                                                  CH3
                                             H



 drisapersenum
 drisapersen                              all-P-ambo-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-
                                          thiocytidylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-
                                          P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-
                                          methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-
                                          O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-
                                          2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-
                                          (3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-
                                          thioguanylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-
                                          P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-
                                          methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-
                                          methyl-P-thiocytidylyl-(3'→5')-2'-O-methyluridine

 drisapersen                              tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-
                                          thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-
                                          P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-
                                          méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-
                                          O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-
                                          2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-
                                          (3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-
                                          thioguanylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-
                                          P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-
                                          méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-
                                          méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyluridine

 drisapersén                              todo-P-ambo-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-
                                          (3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-
                                          (3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioguanilil-
                                          (3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-
                                          (3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-
                                          (3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-
                                          2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-
                                          metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-
                                          tiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-
                                          (3'→5')-2'-O-metiluridina

                                          C211H275N76O119P19S19

                  (3'-5')(P-thio)(Um-Cm-Am-Am-Gm-Gm-Am-Am-Gm-Am-Um-Gm-Gm-Cm-Am-Um-Um-Um-Cm-Um)


 faldaprevirum
 faldaprevir                              (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy-
                                          2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy]-
                                          1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}-
                                          3,3-dimethylbutanoyl]pyrrolidine-2-carboxamido}-
                                          2-ethenylcyclopropane-1-carboxylic acid




306
WHO Drug Information, Vol. 26, No. 3, 2012                                                   Recommended INN: List 68




 faldaprévir                                 acide (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-méthoxy-
                                             2-[2-(2-méthylpropanamido)-1,3-thiazol-4-yl]quinoléin-4-yl}oxy]-
                                             1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}-
                                             3,3-diméthylbutanoyl]pyrrolidine-2-carboxamido}-
                                             2-éthénylcyclopropane-1-carboxylique

 faldaprevir                                 ácido (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy-
                                             2-[2-(2-metilpropanamido)-1,3-tiazol-4-il]quinolin-4-il}oxi]-
                                             1-[(2S)-2-{[(ciclopentiloxi)carbonil]amino}-
                                             3,3-dimetilbutanoil]pirrolidina-2-carboxamido}-2-etenilciclopropano-
                                             1-carboxílico

                                             C40H49BrN6O9S
                                                                                         S
                                                                        Br
                                                                                                NH   CH3
                                                             H3CO                N
                                                                                         N
                                                                                                O    CH3
                                                                 CH3         H
                                                         H3 C
                                                                  CH3            O
                                                         O
                                                                    H
                                                                        N            H
                                                     O       N                       N   CO2H
                                                             H
                                                                    O        H
                                                                                 O           CH2
                                                                                         H



 flanvotumabum #
 flanvotumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens TYRP1 (tyrosinase-
                                             related protein 1, 5,6-dihydroxyindole-2-carboxylic acid oxidase,
                                             DHICA oxidase, TRP1, melanoma antigen gp75)], Homo sapiens
                                             monoclonal antibody;
                                             gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV7-4-1*02
                                             (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                             (222-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                                             V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -
                                             IGKC*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer

 flanvotumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens TYRP1 (protéine 1
                                             apparentée à la tyrosinase, oxydase de l'acide 5,6-dihydroxyindole-
                                             2-carboxylique, DHICA-oxydase, TRP1, antigène gp75 du
                                             mélanome)], Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02
                                             (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                             (222-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-
                                             108') -IGKC*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure

 flanvotumab                                 inmunoglobulina G1-kappa, anti-[TYRP1 de Homo sapiens (proteina
                                             1 relacionada con la tirosinasa), oxidasa del ácido 5,6-dihidroxiindol-
                                             2-carboxílico, DHICA-oxidasa, TRP1, antígeno gp75 de melanoma)],
                                             anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02
                                             (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
                                             (222-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
                                             sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-
                                             108') -IGKC*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro




                                                                                                                    307
Recommended INN: List 68                                    WHO Drug Information, Vol. 26, No. 3, 2012




                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGSE LKKPGASVKI SCKASGYTFT                   SYAMNWVRQA       PGQGLESMGW        50
                           INTNTGNPTY AQGFTGRFVF SMDTSVSTAY                   LQISSLKAED       TAIYYCAPRY       100
                           SSSWYLDYWG QGTLVTVSSA STKGPSVFPL                   APSSKSTSGG       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                   LYSLSSVVTV       PSSSLGTQTY       200
                           ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP                   CPAPELLGGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                   VDGVEVHNAK       TKPREEQYNS       300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                   PAPIEKTISK       AKGQPREPQV       350
                           YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                   VEWESNGQPE       NNYKTTPPVL       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                   HEALHNHYTQ       KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPAT LSLSPGERAT LSCRASQSVS                   SYLAWYQQKP       GQAPRLLIYD 50
                           ASNRATGIPA RFSGSGSGTD FTLTISSLEP                   EDFAVYYCQQ       RSNWLMYTFG 100
                           QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT                   ASVVCLLNNF       YPREAKVQWK 150
                           VDNALQSGNS QESVTEQDSK DSTYSLSSTL                   TLSKADYEKH       KVYACEVTHQ 200
                           GLSSPVTKSF NRGEC                                                               215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 146-202 263-323               369-427
                                    22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-88' 135'-195'
                                    23'''-88''' 135'''-195'''
                           Inter-H-L 222-215' 222''-215'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''




 follitropinum gamma #
 follitropin gamma         heterodimer of human glycoprotein hormones alpha chain and
                           follitropin subunit beta (FSH-beta), follicle stimulating hormone,
                           glycoform gamma

 follitropine gamma        hétérodimère constitué de la chaîne alpha des hormones
                           glycoprotéiques et de la sous-unité bêta de la follitropine (FSH-bêta)
                           humaines, hormone folliculostimulante, forme glycosylée gamma

 folitropina gamma         heterodímero formado por la cadena alfa de las hormonas
                           glicoprotéicas y la subunidad beta de la folitropina (FSH-beta)
                           humanas, hormona estimulante del folículo, forma glicosilada
                           gamma

                           C975H1493N267O305S26 (peptide)

                           Alpha subunit / Sous-unité alpha / Subunidad alfa
                           APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ                                50
                           KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYYH KS                                        92

                           Beta subunit / Sous-unité bêta / Subunidad beta
                           NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
                           CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100'
                           PSYCSFGEMK E                                           111'

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           7-31 10-60 28-82           32-84 59-87
                           3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'

                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-7' Asn-24' Asn-52 Asn-78
                                               R66-                                R
                                                        -Man6-
                           R33--Gal4--Gl-N2-                                           -Gl-NN
                                                                    -Man--Gl-N
                                               R44-
                                                        -Man3-
                           R33--Gal4--Gl-N2-
                           R = -Fuc or H, R3 = -Sia or H, R4 and R6 = R33--Gal4--Gl-N or H




308
WHO Drug Information, Vol. 26, No. 3, 2012                                                  Recommended INN: List 68




 gemcitabini elaidas
 gemcitabine elaidate                        2'-deoxy-2',2'-difluorocytidine 5'-(9E)-octadec-9-enoate

 élaïdate de gemcitabine                     5'-(9E)-octadéc-9-énoate de 2'-déoxy-2',2'-difluorocytidine

 elaidato de gemcitabina                     5'-(9E)-octadec-9-enoato de 2'-desoxi-2',2'-difluorocitidina

                                             C27H43F2N3O5

                                                                                            NH2

                                                                                        N

                                                                            O       O       N
                                                                                    O
                                                                        O               F

                                                               CH3
                                                                                  OH    F




 glyceroli phenylbutyras
 glycerol phenylbutyrate                     propane-1,2,3-triyl tris(4-phenylbutanoate)

 phénylbutyrate de glycérol                  tris(4-phénylbutanoate) de propane-1,2,3-triyle

 fenilbutirato de glicerol                   tris(4-fenilbutanoato) de propano-1,2,3-triilo

                                             C33H38O6

                                                                            O

                                                                        O
                                                               O            O

                                                                   O    O




 idursulfasum beta #
 idursulfase beta                            iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), human pro-
                                             enzyme produced in CHO cells (glycoform beta)

 idursulfase bêta                            iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), proenzyme
                                             humaine produite par des cellules CHO (glycoforme bêta)

 idursulfasa beta                            iduronato 2-sulfatasa (α-L-iduronato sulfato sulfatasa), proenzima
                                             humana producida por células CHO (forma glicosilada beta)




                                                                                                                   309
Recommended INN: List 68                                     WHO Drug Information, Vol. 26, No. 3, 2012




                           C2689H4051N699O793S13

                           SETQANSTTD       ALNVLLIIVD       DLRPSLGCYG      DKLVRSPNID       QLASHSLLFQ       50
                           NAFAQQAVCA       PSRVSFLTGR       RPDTTRLYDF      NSYWRVHAGN       FSTIPQYFKE       100
                           NGYVTMSVGK       VFHPGISSNH       TDDSPYSWSF      PPYHPSSEKY       ENTKTCRGPD       150
                           GELHANLLCP       VDVLDVPEGT       LPDKQSTEQA      IQLLEKMKTS       ASPFFLAVGY       200
                           HKPHIPFRYP       KEFQKLYPLE       NITLAPDPEV      PDGLPPVAYN       PWMDIRQRED       250
                           VQALNISVPY       GPIPVDFQRK       IRQSYFASVS      YLDTQVGRLL       SALDDLQLAN       300
                           STIIAFTSDH       GWALGEHGEW       AKYSNFDVAT      HVPLIFYVPG       RTASLPEAGE       350
                           KLFPYLDPFD       SASQLMEPGR       QSMDLVELVS      LFPTLAGLAG       LQVPPRCPVP       400
                           SFHVELCREG       KNLLKHFRFR       DLEEDPYLPG      NPRELIAYSQ       YPRPSDIPQW       450
                           NSDKPSLKDI       KIMGYSIRTI       DYRYTVWVGF      NPDEFLANFS       DIHAGELYFV       500
                           DSDPLQDHNM       YNDSQGGDLF       QLLMP                                             525

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           146-159 397-407

                           Modified residue / Résidu modifié / Residuo modificado
                                C                  H   NH2
                                59            O
                             3-oxoAla                   CO2H


                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-6 Asn-90 Asn-119 Asn-221 Asn-255 Asn-300 Asn-488 Asn-512




 inclacumabum #
 inclacumab                immunoglobulin G4-kappa, anti-[Homo sapiens SELP (selectin P,
                           CD62)], Homo sapiens monoclonal antibody;
                           gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-13*01
                           (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 hinge
                           S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfide with
                           kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01
                           (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (230-
                           230'':233-233'')-bisdisulfide dimer

 inclacumab                immunoglobuline G4-kappa, anti-[Homo sapiens SELP (sélectine P,
                           CD62)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01
                           (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 charnière
                           S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfure
                           avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA
                           (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01
                           (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure

 inclacumab                inmunoglobulina G4-kappa, anti-[SELP de Homo sapiens (selectina
                           P, CD62)], anticuerpo monoclonal de Homo sapiens ;
                           cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01
                           (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 bisagra
                           S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfuro con
                           la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-
                           11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
                           dímero (230-230'':233-233'')-bisdisulfuro




310
WHO Drug Information, Vol. 26, No. 3, 2012                                                            Recommended INN: List 68




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVRPGGSLRL SCAASGFTFS                  NYDMHWVRQA       TGKGLEWVSA        50
                                             ITAAGDIYYP GSVKGRFTIS RENAKNSLYL                  QMNSLRAGDT       AVYYCARGRY       100
                                             SGSGSYYNDW FDPWGQGTLV TVSSASTKGP                  SVFPLAPCSR       STSESTAALG       150
                                             CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                  LQSSGLYSLS       SVVTVPSSSL       200
                                             GTKTYTCNVD HKPSNTKVDK RVESKYGPPC                  PPCPAPEFEG       GPSVFLFPPK       250
                                             PKDTLMISRT PEVTCVVVDV SQEDPEVQFN                  WYVDGVEVHN       AKTKPREEQF       300
                                             NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  GLPSSIEKTI       SKAKGQPREP       350
                                             QVYTLPPSQE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                                             VLDSDGSFFL YSRLTVDKSR WQEGNVFSCS                  VMHEALHNHY       TQKSLSLSLG       450
                                             K                                                                                   451

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD 50
                                             ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCQQ       RSNWPLTFGG 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-95 151-207             265-325   371-429
                                                      22''-95'' 151''-207'' 265''-325'' 371''-429''
                                             Intra-L 23'-88'       134'-194'
                                                       23'''-88''' 134'''-194'''
                                             Inter-H-L 138-214' 138''-214'''
                                             Inter-H-H 230-230'' 233-233''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             301, 301''




 lucerastatum
 lucerastat                                  (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

 lucérastat                                  (2R,3S,4R,5S)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol

 lucerastat                                  (2R,3S,4R,5S)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol


                                             C10H21NO4

                                                       OH
                                                            H
                                             HO
                                               H
                                                            N              CH3
                                             HO
                                                   H        H
                                                           OH



 naltalimidum
 naltalimide                                 2-[17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-
                                             6β-yl]isoindole-1,3-dione

 naltalimide                                 2-[-17-(cyclopropylméthyl)-4,5α-époxy-3,14-dihydroxymorphinan-
                                             6β-yl]-2H-isoindole-1,3-dione

 naltalimida                                 2-[17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroximorfinan-
                                             6β-il]isoindol-1,3-diona




                                                                                                                                         311
Recommended INN: List 68                                      WHO Drug Information, Vol. 26, No. 3, 2012


                           C28H28N2O5

                                         H    N

                                         HO
                                                              O

                                          O               N
                           HO                 H H

                                                      O



 netazepidum
 netazepide                1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-
                           2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-
                           3-[3-(methylamino)phenyl]urea

 nétazépide                1-[(3R)-1-(3,3-diméthyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-
                           2,3-dihydro-1H-1,4-benzodiazépin-3-yl]-
                           3-[3-(méthylamino)phényl]urée

 netazepida                1-[(3R)-1-(3,3-dimetil-2-oxobutil)-2-oxo-5-(piridin-2-il)-2,3-dihidro-
                           1H-1,4-benzodiazepin-3-il]-3-[3-(metilamino)fenil]urea

                           C28H30N6O3

                                     CH3
                           H3C         CH3
                                                                       CH3
                                                                  HN
                                 O                O
                                          N               O
                                                      H
                                                      N       N
                                              N       H       H

                                     N




 niraparibum
 niraparib                 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide

 niraparib                 2-{4-[(3S)-pipéridin-3-yl]phényl}-2H-indazole-7-carboxamide

 niraparib                 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida

                           C19H20N4O

                              H
                              N

                                                      N
                                     H                    N

                                                              O    NH2




312
WHO Drug Information, Vol. 26, No. 3, 2012                                                Recommended INN: List 68


 ondelopranum
 ondelopran                                  6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine-
                                             3-carboxamide

 ondélopran                                  6-[2-fluoro-4-({[2-(oxan-4-yl)éthyl]amino}méthyl)phénoxy]pyridine-
                                             3-carboxamide

 ondeloprán                                  6-[2-fluoro-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]piridina-
                                             3-carboxamida

                                             C20H24FN3O3

                                             O                                            O

                                                                N                   N         NH2
                                                                H
                                                                                O
                                                                           F



 patiromerum calcium
 patiromer calcium                           cross-linked polymer of calcium 2-fluoroprop-2-enoate with
                                             diethenylbenzene and octa-1,7-diene

 patiromère calcique                         polymère réticulé de 2-fluoroprop-2-énoate de calcium avec du
                                             diéthénylbenzène et de l'octa-1,7-diène

 patirómero cálcico                          polímero reticulado de 2-fluoroprop-2-enoato de calcio con
                                             dietenilbenceno y octa-1,7-dieno

                                             [[(C3H2FO2)2 Ca]9 [C8H14] [C10H10]]n


                                               H2C       CO2                            CH2

                                                     F                    H2C
                                                                x                             y


                                                  x/2 Ca   2+                           CH2
                                                                    H2C
                                                                                              z




 patritumabum #
 patritumab                                  immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3 (receptor
                                             tyrosine-protein kinase erbB-3, HER3)], Homo sapiens monoclonal
                                             antibody;
                                             gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV4-34*01
                                             (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
                                             (220-220')-disulfide with kappa light chain (1'-220') [Homo sapiens
                                             V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -
                                             IGKC*01 (114'-220')]; (226-226'':229-229'')-bisdisulfide dimer

 patritumab                                  immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3 (récepteur
                                             tyrosine-protéine kinase erbB3, HER3)], Homo sapiens anticorps
                                             monoclonal;
                                             chaîne lourde gamma1 (1-447) [Homo sapiens VH (IGHV4-34*01
                                             (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
                                             (220-220')-disulfure avec la chaîne légère kappa (1'-220') [Homo
                                             sapiens V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-
                                             113') -IGKC*01 (114'-220')]; dimère (226-226'':229-229'')-bisdisulfure




                                                                                                                  313
Recommended INN: List 68                                     WHO Drug Information, Vol. 26, No. 3, 2012


 patritumab                inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3 (receptor de
                           tirosina-proteina kinasa erbB3, HER3)], anticuerpo monoclonal de
                           Homo sapiens;
                           cadena pesada gamma1 (1-447) [Homo sapiens VH (IGHV4-34*01
                           (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
                           (220-220')-disulfuro con la cadena ligera kappa (1'-220') [Homo
                           sapiens V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-
                           113') -IGKC*01 (114'-220')]; dímero (226-226'':229-229'')-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQWGAG LLKPSETLSL TCAVYGGSFS                   GYYWSWIRQP      PGKGLEWIGE        50
                           INHSGSTNYN PSLKSRVTIS VETSKNQFSL                   KLSSVTAADT      AVYYCARDKW       100
                           TWYFDLWGRG TLVTVSSAST KGPSVFPLAP                   SSKSTSGGTA      ALGCLVKDYF       150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                   SLSSVVTVPS      SSLGTQTYIC       200
                           NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP                   APELLGGPSV      FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                   GVEVHNAKTK      PREEQYNSTY       300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                   PIEKTISKAK      GQPREPQVYT       350
                           LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                   WESNGQPENN      YKTTPPVLDS       400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                   ALHNHYTQKS      LSLSPGK          447

                           Light chain / Chaîne légère / Cadena ligera
                           DIEMTQSPDS LAVSLGERAT INCRSSQSVL                   YSSSNRNYLA      WYQQNPGQPP 50
                           KLLIYWASTR ESGVPDRFSG SGSGTDFTLT                   ISSLQAEDVA      VYYCQQYYST 100
                           PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ                   LKSGTASVVC      LLNNFYPREA 150
                           KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                   LSSTLTLSKA      DYEKHKVYAC 200
                           EVTHQGLSSP VTKSFNRGEC                                                         220

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-95        144-200       261-321  367-425
                                     22''-95'' 144''-200'' 261''-321'' 367''-425''
                           Intra-L 23'-94'      140'-200'
                                    23'''-94''' 140'''-200'''
                           Inter-H-L 220-220' 220''-220'''
                           Inter-H-H 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           297, 297''



 plazomicinum
 plazomicin                (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-
                           6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2H-pyran-2-yl]oxy}-
                           2-{[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl]oxy}-
                           3-hydroxycyclohexyl]-2-hydroxybutanamide

 plazomicine               (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-
                           6-{[(2-hydroxyéthyl)amino]méthyl}-3,4-dihydro-2H-pyran-2-yl]oxy}-
                           2-{[3-déoxy-4-C-méthyl-3-(méthylamino)-β-L-arabinopyranosyl]oxy}-
                           3-hydroxycyclohexyl]-2-hydroxybutanamide

 plazomicina               (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-
                           6-{[(2-hidroxietil)amino]metil}-3,4-dihidro-2H-piran-2-il]oxi}-
                           2-{[3-desoxi-4-C-metil-3-(metilamino)-β-L-arabinopiranosil]oxi}-
                           3-hidroxiciclohexil]-2-hidroxibutanamida

                           C25H48N6O10
                                            HO           O
                                                       CH3                  O
                           HO                    HN
                                                                                            NH2
                                           H3C                   O    HN
                                    HN                 OH                     H OH
                                                    O HO


                                                                        NH2
                                                    NH2      O


 pradigastatum
 pradigastat               {(1r,4r)-4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)
                           phenyl]cyclohexyl}acetic acid


314
WHO Drug Information, Vol. 26, No. 3, 2012                                                          Recommended INN: List 68




 pradigastat                                 acide {trans-4-[4-(5-{[6-(trifluorométhyl)pyridin-3-yl]amino}pyridin-
                                             2-yl)phényl]cyclohexyl}acétique

 pradigastat                                 ácido {(1r,4r)-4-[4-(5-{[6-(trifluorometil)piridin-3-il]amino}piridin-2-il)
                                             fenil]ciclohexil}acético

                                             C25H24F3N3O2
                                                                                                       CO2H



                                             F 3C       N          N


                                                             N
                                                             H

 pritelivirum
 pritelivir                                  N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-
                                             2-yl)phenyl]acetamide

 pritélivir                                  N-méthyl-N-(4-méthyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-
                                             2-yl)phényl]acétamide

 pritelivir                                  N-metil-N-(4-metil-5-sulfamoil-1,3-tiazol-2-il)-2-[4-(pyridin-
                                             2-il)fenil]acetamida

                                             C18H18N4O3S2

                                                    N
                                                                                    CH3
                                                                    O       N                 NH2
                                                                                          S
                                                                        N       S             O
                                                                                      O
                                                                        CH3



 quilizumabum #
 quilizumab                                  immunoglobulin G1-kappa, anti-[Homo sapiens IGHE connecting
                                             region (CO) M1 prime (in alternatively spliced heavy chain of
                                             membrane IgE on B cells)], humanized monoclonal antibody;
                                             gamma1 heavy chain (1-447) [humanized VH (Homo sapiens
                                             IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-
                                             117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220-
                                             219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA
                                             (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112')
                                             -Homo sapiens IGKC*01 (113'-219')]; (226-226":229-229")-
                                             bisdisulfide dimer

 quilizumab                                  immunoglobuline G1-kappa, anti-[Homo sapiens IGHE région de
                                             connexion (CO) M1 prime (dans la chaîne lourde des IgE
                                             membranaires à la surface des lymphocytes B, épissée de manière
                                             alternative)], anticorps monoclonal humanisé;
                                             chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens
                                             IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-
                                             117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220-
                                             219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
                                             humanisé (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
                                             [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (226-
                                             226":229-229")-bisdisulfure


                                                                                                                           315
Recommended INN: List 68                                    WHO Drug Information, Vol. 26, No. 3, 2012


 quilizumab                inmunoglobulina G1-kappa, anti-[Homo sapiens IGHE región de
                           conexión (CO) M1 prime (en la cadena pesada de las IgE de
                           membrana de la superficie de los linfocitos B, ensamblada de modo
                           alternativo)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens
                           IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-
                           117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220-
                           219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                           humanizado (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (226-
                           226":229-229")-bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  DYGIAWVRQA       PGKGLEWVAF        50
                           ISDLAYTIYY ADTVTGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARDN       100
                           WDAMDYWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                           NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                           LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRSSQSLV                  HNNANTYLHW       YQQKPGKAPK 50
                           LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI                  SSLQPEDFAT       YYCSQNTLVP 100
                           WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        144-200       261-321  367-425
                                    22''-96'' 144''-200'' 261''-321'' 367''-425''
                           Intra-L 23'-93'       139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 220-219' 220''-219'''
                           Inter-H-H 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           297, 297'' (non-fucosylated oligosaccharides)

 radavirsenum
 radavirsen                all-P-ambo-P,2',3'-trideoxy-P-(dimethylamino)-5'-O-{P-[4-({2-[2-(2-
                           hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-N,N-
                           dimethylphosphonamidoyl}-(2'a→5')-P,2',3'-trideoxy-P-
                           (dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-
                           trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a→5')-
                           P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-
                           (2'a→5')-P,3'-dideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'-
                           secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-
                           2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-
                           imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-
                           2',3'-imino-2',3'-secoguanyly-(2'a→5')-P,2',3'-trideoxy-P-
                           (dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-
                           trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-
                           P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-
                           (2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-
                           secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-
                           2',3'-secocytidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-
                           imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-
                           (dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-
                           trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-
                           P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl-
                           (2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'-
                           secocytidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-
                           2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-
                           imino-2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-
                           2',3'-imino-2',3'-secothymidine


316
WHO Drug Information, Vol. 26, No. 3, 2012                                                Recommended INN: List 68




 radavirsen                                  tout-P-ambo-P,2',3'-tridéoxy-P-(diméthylamino)-5'-O-{P-[4-({2-[2-(2-
                                             hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-N,N-
                                             diméthylphosphonamidoyl}-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-
                                             P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-
                                             (2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-
                                             sécoguanylyl-(2'a→5')-P,3'-didéoxy-2',3'-imino-P-(pipérazin-1-yl)-
                                             2',3'-sécothymidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-2',3'-
                                             imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridéoxy-P-
                                             (diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-
                                             tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-
                                             P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-
                                             (2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-
                                             sécoadenylyl-(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-
                                             2',3'-sécoguanylyl-(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-
                                             imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridéoxy-2',3'-imino-P-
                                             (pipérazin-1-yl)-2',3'-sécocytidylyl-(2'a→5')-P,3'-didéoxy-P-
                                             (diméthylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-
                                             tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-
                                             P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-
                                             (2'a→5')-P,3'-didéoxy-P-(dimethylamino)-2',3'-imino-2',3'-
                                             sécothymidylyl-(2'a→5')-P,2',3'-tridéoxy-2',3'-imino-P-(pipérazin-1-
                                             yl)-2',3'-sécocytidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-2',3'-
                                             imino-2',3'-sécothymidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-
                                             2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-3'-déoxy-2',3'-imino-2',3'-
                                             sécothymidine



 radavirsén                                  todo-P-ambo-P,2',3'-tridesoxi-P-(dimetilamino)-5'-O-{P-[4-({2-[2-(2-
                                             hidroxietoxi)etoxi]etoxi}carbonil)piperazin-1-il]-N,N-
                                             dimetilfosfonamidoil}-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-
                                             imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-
                                             2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-
                                             (dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,3'-didesoxi-P-
                                             (piperazin-1-il)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-didesoxi-P-
                                             (dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-
                                             P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-
                                             tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-
                                             P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-
                                             (2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-
                                             secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-
                                             2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-
                                             imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-(piperazin-1-il)-
                                             2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'-didesoxi-P-(dimetilamino)-
                                             2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-
                                             (dimetilamino)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-
                                             P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,3'-didesoxi-
                                             P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-
                                             tridesoxi-P-(piperazin-1-il)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'-
                                             didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-
                                             didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-
                                             didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidina




                                                                                                                      317
Recommended INN: List 68                                              WHO Drug Information, Vol. 26, No. 3, 2012




                           C253H398N116O87P20

                                          O                                      B(n)                            B(20)

                                     O            N                            O 1'                          O
                                                                                  2'a
                           HO                                N        O                 N           O               NH
                                          3                       P                         P
                                                                          5'
                                                      H 3C       N O                    R(n) O          19
                           n = 1 - 19                             CH3

                                B(1-20) : C-G-G-T-T-A-G-A-A-G-A-C-T-C-A-T-C-T-T-T

                                R(1-3) = R(5-11) = R(13-16) = R(18) = R(19) = -N(CH3)2


                                                  R(4) = R(12) = R(17) = HN                     N



 rafigrelidum
 rafigrelide               6,7-dichloro-3,3-dimethyl-5,10-dihydroimidazo[2,1-b]quinazolin-
                           2(3H)-one

 rafigrélide               6,7-dichloro-3,3-diméthyl-1,5-dihydroimidazo[2,1-b]quinazolin-
                           2(3H)-one

 rafigrelida               6,7-dicloro-3,3-dimetil-5,10-dihidroimidazo[2,1-b]quinazolin-
                           2(3H)-ona

                           C12H11Cl2N3O

                                                             H
                                                  N          N
                                                                      O
                                                      N
                           Cl
                                                                 CH3
                                     Cl                H3C


 refametinibum
 refametinib               N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-
                           1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide

 réfamétinib               N-{3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl}-
                           1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide

 refametinib               N-{3,4-difluoro-2-[(2-fluoro-4-iodofenil)amino]-6-metoxifenil}-
                           1-[(2S)-2,3-dihidroxipropil]ciclopropano-1-sulfonamida

                           C19H20F3IN2O5S

                                                          CH3
                                 F                        O
                                                           O O
                                                            S
                                 F                        N                       OH
                                                          H
                                              NH                          H OH


                           I                  F




318
WHO Drug Information, Vol. 26, No. 3, 2012                                                   Recommended INN: List 68




 rigosertibum
 rigosertib                                  N-[2-methoxy-5-({[(1E)-2-(2,4,6-
                                             trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine

 rigosertib                                  N-[2-méthoxy-5-({[(1E)-2-(2,4,6-
                                             triméthoxyphényl)éthényl]sulfonyl}méthyl)phényl]glycine

 rigosertib                                  N-[2-metoxi-5-({[(1E)-2-(2,4,6-
                                             trimetoxifenil)etenil]sulfonil}metil)fenil]glicina

                                             C21H25NO8S

                                             H3CO                OCH3
                                                                                      H
                                                                                      N      CO2H
                                                                        S
                                                          OCH3      O O
                                                                                      OCH3


 riodipinum
 riodipine                                   dimethyl 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-
                                             1,4-dihydropyridine-3,5-dicarboxylate

 riodipine                                   4-[2-(difluorométhoxy)phényl]-2,6-diméthyl-1,4-dihydropyridine-
                                             3,5-dicarboxylate de diméthyle

 riodipino                                   4-[2-(difluorometoxi)fenil]-2,6-dimetil-1,4-dihidropiridina-
                                             3,5-dicarboxilato de dimetilo

                                             C18H19F2NO5

                                                             H
                                                    H3C      N      CH3

                                                   O                    O
                                             H3C                                CH3
                                                       O            O
                                                                    O           F

                                                                            F


 romosozumabum #
 romosozumab                                 immunoglobulin G2-kappa, anti-[Homo sapiens SOST (sclerostin)],
                                             humanized monoclonal antibody;
                                             gamma2 heavy chain (1-449) [humanized VH (Homo sapiens
                                             IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T
                                             (118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137-
                                             214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA
                                             (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -
                                             Homo sapiens IGKC*01 (108'-214')]; (225-225":226-226":229-
                                             229":232-232")-tetrakisdisulfide dimer

 romosozumab                                 immunoglobuline G2-kappa, anti-[Homo sapiens SOST
                                             (sclérostine)], anticorps monoclonal humanisé;
                                             chaîne lourde gamma2 (1-449) [VH humanisé (Homo sapiens
                                             IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T
                                             (118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137-
                                             214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
                                             humanisé (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9]
                                             (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (225-
                                             225":226-226":229-229":232-232")-tétrakisdisulfure


                                                                                                                  319
Recommended INN: List 68                                     WHO Drug Information, Vol. 26, No. 3, 2012


 romosozumab               inmunoglobulina G2-kappa, anti-[SOST (esclerostina) de Homo
                           sapiens], anticuerpo monoclonal humanizado;
                           cadena pesada gamma2 (1-449) [VH humanizado (Homo sapiens
                           IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T
                           (118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137-
                           214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA
                           humanizado (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02)
                           [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (225-
                           225":226-226":229-229":232-232")-tetrakisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGASVKV SCKASGYTFT                  DYNMHWVRQA       PGQGLEWMGE        50
                           INPNSGGAGY NQKFKGRVTM TTDTSTSTAY                  MELRSLRSDD       TAVYYCARLG       100
                           YDDIYDDWYF DVWGQGTTVT VSSASTKGPS                  VFPLAPCSRS       TSESTAALGC       150
                           LVKDYFPEPV TVSWNSGALT SGVHTFPAVL                  QSSGLYSLSS       VVTVPSSNFG       200
                           TQTYTCNVDH KPSNTKVDKT VERKCCVECP                  PCPAPPVAGP       SVFLFPPKPK       250
                           DTLMISRTPE VTCVVVDVSH EDPEVQFNWY                  VDGVEVHNAK       TKPREEQFNS       300
                           TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL                  PAPIEKTISK       TKGQPREPQV       350
                           YTLPPSREEM TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPML       400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK        449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCRASQDIS                  NYLNWYQQKP       GKAPKLLIYY 50
                           TSRLLSGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQQ       GDTLPYTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 150-206              263-323  369-427
                                    22''-96'' 150''-206'' 263''-323'' 369''-427''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 137-214' 137''-214'''
                           Inter-H-H 225-225'' 226-226'' 229-229'' 232-232''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''



 samidorphanum
 samidorphan               17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan-
                           3-carboxamide

 samidorphan               17-(cyclopropylméthyl)-4,14-dihydroxy-6-oxomorphinane-
                           3-carboxamide

 samidorfano               17-(ciclopropilmetil)-4,14-dihidroxi-6-oxomorfinan-3-carboxamida

                           C21H26N2O4
                                             H    N


                                            HO



                           H2N             OH            O
                                     O

 sapitinibum
 sapitinib                 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-
                           6-yl}oxy)piperidin-1-yl]-N-methylacetamide

 sapitinib                 2-[4-({4-[(3-chloro-2-fluorophényl)amino]-7-méthoxyquinazolin-
                           6-yl}oxy)pipéridin-1-yl]-N-méthylacétamide




320
WHO Drug Information, Vol. 26, No. 3, 2012                                                              Recommended INN: List 68


 sapitinib                                   2-[4-({4-[(3-cloro-2-fluorofenil)amino]-7-metoxiquinazolin-
                                             6-il}oxi)piperidin-1-il]-N-metilacetamida


                                             C23H25ClFN5O3
                                                                             CH3
                                                    H
                                                    N                        O                N
                                             H3 C               N
                                                        O                                         N
                                                                             O                        F
                                                                                            HN                Cl




 sarilumabum #
 sarilumab                                   immunoglobulin G1-kappa, anti-[Homo sapiens IL6R (interleukin 6
                                             receptor, IL-6R, CD126)], Homo sapiens monoclonal antibody;
                                             gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV3-9*01
                                             (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
                                             (219-214')-disulfide with kappa light chain (1'-214') [Homo sapiens
                                             V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -
                                             IGKC*01 (108'-214')]; (225-225'':228-228'')-bisdisulfide dimer

 sarilumab                                   immunoglobuline G1-kappa, anti-[Homo sapiens IL6R (récepteur de
                                             l'interleukine 6, IL-6R, CD126)], Homo sapiens anticorps
                                             monoclonal;
                                             chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV3-9*01
                                             (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
                                             (219-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo
                                             sapiens V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-
                                             107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure

 sarilumab                                   inmunoglobulina G1-kappa, anti-[Homo sapiens IL6R (receptor de la
                                             interleukina 6, IL-6R, CD126)], anticuerpo monoclonal de Homo
                                             sapiens;
                                             cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV3-9*01
                                             (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
                                             (219-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo
                                             sapiens V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-
                                             107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGRSLRL SCAASRFTFD                  DYAMHWVRQA       PGKGLEWVSG        50
                                             ISWNSGRIGY ADSVKGRFTI SRDNAENSLF                  LQMNGLRAED       TALYYCAKGR       100
                                             DSFDIWGQGT MVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                                             EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                                             VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA                  PELLGGPSVF       LFPPKPKDTL       250
                                             MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                                             VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                                             PPSRDELTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                                             GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS VSASVGDRVT ITCRASQGIS                  SWLAWYQQKP       GKAPKLLIYG 50
                                             ASSLESGVPS RFSGSGSGTD FTLTISSLQP                  EDFASYYCQQ       ANSFPYTFGQ 100
                                             GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H 22-96        143-199       260-320  366-424
                                                       22''-96'' 143''-199'' 260''-320'' 366''-424''
                                             Intra-L 23'-88'      134'-194'
                                                      23'''-88''' 134'''-194'''
                                             Inter-H-L 219-214' 219''-214'''
                                             Inter-H-H 225-225'' 228-228''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             296, 296''



                                                                                                                                               321
Recommended INN: List 68                                 WHO Drug Information, Vol. 26, No. 3, 2012




 secretinum humanum
 secretin human            human peptide hormone secretin;
                           L-histidyl-L-seryl-L-aspartylglycyl-L-threonyl-L-phenylalanyl-
                           L-threonyl-L-seryl-L-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-
                           L-arginyl-L-glutamylglycyl-L-alanyl-Larginyl-L-leucyl-L-glutaminyl-
                           L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide

 sécrétine humaine         sécrétine humaine hormone peptidique;
                           L-histidyl-L-séryl-L-aspartylglycyl-L-thréonyl-L-phénylalanyl-
                           L-thréonyl-L-séryl-L-glutamyl-L-leucyl-L-séryl-L-arginyl-L-leucyl-
                           L-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-
                           L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide

 secretina humana          secretina humana, hormona peptídica;
                           L-histidil-L-seril-L-aspartilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-
                           L-glutamil-L-leucil-L-seril-L-arginil-L-leucil-L-arginil-L-glutamilglicil-
                           L-alanil-L-arginil-L-leucil-L-glutaminil-L-arginil-L-leucil-L-leucil-
                           L-glutaminilglicil-L-leucil-L-valinamida

                           C130 H220 N44 O40

                           HSDGTFTSEL SRLREGARLQ RLLQGLV                   27

                           Modified residue / Résidu modifié / Residuo modificado
                                                          H    NH2
                                V                 H3C                NH2
                                27
                           valinamide
                                                         CH3   O



 selisistatum
 selisistat                rac-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide

 sélisistat                rac-6-chloro-2,3,4,9-tétrahydro-1H-carbazole-1-carboxamide

 selisistat                rac-6-cloro-2,3,4,9-tetrahidro-1H-carbazol-1-carboxamida

                           C13H13ClN2O
                                           H         O
                                           N     H
                                                                and enantiomer
                                                         NH2    et énantiomère
                                                                y enantiómero
                           Cl




 setrobuvirum
 setrobuvir                N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-
                           1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-
                                          6
                           1,4-dihydro-1λ ,2,4-benzothiadiazin-7-yl)methanesulfonamide

 sétrobuvir                N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophényl)méthyl]-4-hydroxy-2-oxo-
                           1,2,4a,5,6,7,8,8a-octahydro-5,8-méthanoquinoléin-3-yl}-1,1-dioxo-
                                          6
                           1,4-dihydro-1λ ,2,4-benzothiadiazin-7-yl)méthanesulfonamide

 setrobuvir                N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorofenil)metil]-4-hidroxi-2-oxo-
                           1,2,4a,5,6,7,8,8a-octahidro-5,8-metanoquinolin-3-il}-1,1-dioxo-
                                         6
                           1,4-dihidro-1λ ,2,4-benzotiadiazin-7-il)metanosulfonamida




322
WHO Drug Information, Vol. 26, No. 3, 2012                                             Recommended INN: List 68


                                             C25H25FN4O6S2
                                                                    F


                                               H
                                                   H
                                                       N    O
                                                                H
                                                                N
                                                                           O O
                                                   H
                                               H       OH   N               S
                                                                S         N   CH3
                                                                          H
                                                             O O

 sevuparinum natricum
 sevuparin sodium                            sodium salt of a low molecular mass heparin obtained by
                                             depolymerization through periodate oxidation of heparin from porcine
                                             intestinal mucosa, followed by reduction and mild acid hydrolysis of
                                             the product; the majority of the components have a 2-amino-
                                             2-deoxy-D-glucopyranose derivative structure at both ends of their
                                             chain, the one at the reducing end can be substituted with threonic
                                             acid or erythronic acid; the relative average molecular mass range is
                                             approximately 7,500 daltons with about 90% ranging between 2,000
                                             and 15,000 daltons; the degree of sulfation is 2 to 2.5 per
                                             disaccharidic unit

 sévuparine sodique                          sel sodique d'une héparine de basse masse moléculaire obtenue par
                                             dépolymérisation, au moyen d'une oxydation periodique, d'héparine
                                             de muqueuse intestinale de porc, suivi par une réduction et par une
                                             hydrolyse douce; la majorité des composants de la sévuparine
                                             sodique possèdent une structure 2-amino-2-déoxy-D-glucopyranose
                                             aux deux extrémités, la réductrice peut être substituée par un acide
                                             thréonique ou érythronique; la masse moléculaire relative moyenne
                                             est approximativement de 7500 daltons, et celles de 90% sont
                                             comprises entre 2000 à 15000; le degré de sulfatation est de 2 à 2,5
                                             par unité disaccharide.

 sevuparina sódica                           sal sódica de una heparina de baja masa molecular obtenida por
                                             despolimerización, mediante oxidación periodica, de heparina de
                                             mucosa intestinal porcina, seguida de reducción e hidrólisis con
                                             ácido débil; la mayoría de los componentes de la sevuparina sódica
                                             tienen una estructura 2-amino-2-desoxi-D-glucopiranosa en los dos
                                             extremos, el reductor puede estar substituido con un ácido treónico
                                             o eritrónico; la masa molecular relativa media es aproximadamente
                                             de 7500 dalton, y con el 90% comprendido entre 2000 y 15000; el
                                             grado de sulfatación es de 2 a 2,5 por unidad de disacárido

 solitomabum #
 solitomab                                   immunoglobulin scFv-scFv, anti-[Homo sapiens EPCAM (epithelial
                                             cell adhesion molecule, tumor-associated calcium signal transducer
                                             1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2,
                                             epithelial glycoprotein 2, EGP-2, KSA, KS1/4 antigen, M4S1, tumor
                                             antigen 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[Homo sapiens
                                             CD3E (CD3 epsilon)], Mus musculus monoclonal antibody bispecific
                                             single chain;
                                             scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01
                                             (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
                                             tris(tetraglycyl-seryl) linker (114-128) -Mus musculus VH (IGHV1-
                                             54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-
                                             248)] -5-mer tetraglycyl-seryl linker (249-253) -scFv anti-CD3E
                                             [humanized VH (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-
                                             IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA
                                             (Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493)
                                             [5.3.9] (391-496)] -hexahistidine (497-502)

                                                                                                                323
Recommended INN: List 68                                    WHO Drug Information, Vol. 26, No. 3, 2012




 solitomab                 immunoglobuline scFv-scFv, anti-[Homo sapiens EPCAM (molécule
                           d'adhésion des cellules épithéliales, transducteur 1 du signal calcium
                           associé aux tumeurs, TACSTD1, protéine 2 associée aux tumeurs
                           gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2,
                           KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, Ep-CAM,
                           EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)], Mus
                           musculus anticorps monoclonal bispécifique à chaîne unique;
                           scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01
                           (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
                           tris(tétraglycyl-séryl) linker (114-128) -Mus musculus VH (IGHV1-
                           54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-
                           248)] -5-mer tétraglycyl-séryl linker (249-253) -scFv anti-CD3E [VH
                           humanisé (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01)
                           [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (Mus
                           musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9]
                           (391-496)] -hexahistidine (497-502)

 solitomab                 inmunoglobulina scFv-scFv, anti-[EPCAM de Homo sapiens
                           (molécula de adhesión de células epiteliales, transductor 1 de la
                           señal de calcio asociado a tumores, TACSTD1, proteina 2 asociada
                           a tumores gastrointestinales, GA733-2, glicoproteina epitelial 2,
                           EGP-2, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, Ep-
                           CAM, EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)],
                           anticuerpo monoclonal biespecifico monocatenario de Mus
                           musculus;
                           scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01
                           (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
                           tris(tetraglicil-seril) conector (114-128) -Mus musculus VH (IGHV1-
                           54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-
                           248)] -5-mer tetraglicil-seril conector (249-253) -scFv anti-CD3E [VH
                           humanizado (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-
                           IGHJ6*01) [8.8.12] (254-372) -18-mer conector (373-390) -V-KAPPA
                           (Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493)
                           [5.3.9] (391-496)] -hexahistidina (497-502)


                           ELVMTQSPSS      LTVTAGEKVT       MSCKSSQSLL       NSGNQKNYLT       WYQQKPGQPP        50
                           KLLIYWASTR      ESGVPDRFTG       SGSGTDFTLT       ISSVQAEDLA       VYYCQNDYSY       100
                           PLTFGAGTKL      EIKGGGGSGG       GGSGGGGSEV       QLLEQSGAEL       VRPGTSVKIS       150
                           CKASGYAFTN      YWLGWVKQRP       GHGLEWIGDI       FPGSGNIHYN       EKFKGKATLT       200
                           ADKSSSTAYM      QLSSLTFEDS       AVYFCARLRN       WDEPMDYWGQ       GTTVTVSSGG       250
                           GGSDVQLVQS      GAEVKKPGAS       VKVSCKASGY       TFTRYTMHWV       RQAPGQGLEW       300
                           IGYINPSRGY      TNYADSVKGR       FTITTDKSTS       TAYMELSSLR       SEDTATYYCA       350
                           RYYDDHYCLD      YWGQGTTVTV       SSGEGTSTGS       GGSGGSGGAD       DIVLTQSPAT       400
                           LSLSPGERAT      LSCRASQSVS       YMNWYQQKPG       KAPKRWIYDT       SKVASGVPAR       450
                           FSGSGSGTDY      SLTINSLEAE       DAATYYCQQW       SSNPLTFGGG       TKVEIKHHHH       500
                           HH                                                                                  502

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-chain 23-94 151-225 275-349 413-477

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           305 (but Pro in 306)




 sovaprevirum
 sovaprevir                (2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(piperidin-1-yl)butanoyl]-
                           N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-
                           2-ethenylcyclopropyl}-4-[(7-methoxy-2-phenylquinolin-
                           4-yl)oxy]pyrrolidine-2-carboxamide




324
WHO Drug Information, Vol. 26, No. 3, 2012                                                           Recommended INN: List 68




 sovaprévir                                  (2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(pipéridin-1-yl)butanoyl]-
                                             N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-
                                             2-éthénylcyclopropyl}-4-[(7-méthoxy-2-phénylquinoléin-
                                             4-yl)oxy]pyrrolidine-2-carboxamide

 sovaprevir                                  (2S,4R)-1-[(2S)-2-terc-butil-4-oxo-4-(piperidin-1-il)butanoil]-
                                             N-{(1R,2S)-1-[(ciclopropanosulfonil)carbamoil]-2-etenilciclopropil}-
                                             4-[(7-metoxi-2-fenilquinolin-4-il)oxi]pirrolidina-2-carboxamida

                                             C43H53N5O8S



                                                            H3CO               N


                                                               CH3         H
                                                        H 3C
                                                                CH3            O
                                                        O
                                                                   H                       O     O O
                                                                       N           H
                                                    N                              N              S
                                                                                                N
                                                                   O       H                    H
                                                                               O
                                                                                           H
                                                                                               CH2



 sutezolidum
 sutezolid                                   N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxo-
                                             1,3-oxazolan-5-yl}methyl)acetamide

 sutézolid                                   N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phényl]-2-oxo-
                                             1,3-oxazolidin-5-yl}méthyl)acétamide

 sutezolid                                   N-({(5S)-3-[3-fluoro-4-(tiomorfolin-4-il)fenil]-2-oxo-1,3-oxazolan-
                                             5-il}metil)acetamida

                                             C16H20FN3O3S

                                                                   O       O
                                                        H H
                                             H 3C       N
                                                                       N               F
                                                    O
                                                                                       N
                                                                                               S



 tanzisertibum
 tanzisertib                                 (1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophenyl)amino]-
                                             9H-purin-2-yl}amino)cyclohexan-1-ol

 tanzisertib                                 (1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophényl)amino]-
                                             9H-purin-2-yl}amino)cyclohexan-1-ol

 tanzisertib                                 (1r,4r)-4-({9-[(3S)-oxolan-3-il]-8-[(2,4,6-trifluorfenil)amino]-9H-purin-
                                             2-il}amino)ciclohexan-1-ol




                                                                                                                          325
Recommended INN: List 68                                   WHO Drug Information, Vol. 26, No. 3, 2012


                           C21H23F3N6O2
                                                                                F

                                                                   F
                                H
                                                               N
                           HO                     N
                                                                           NH   F
                                          N           N        N
                                        H H                H

                                                                       O

 tavaborolum
 tavaborole                5-fluoro-2,1-benzoxaborol-1(3H)-ol

 tavaborole                5-fluoro-2,1-benzoxaborol-1(3H)-ol

 tavaborol                 5-fluoro-2,1-benzoxaborol-1(3H)-ol

                           C7H6BFO2
                                             OH
                                         B
                                             O
                           F

 tedatioxetinum
 tedatioxetine             4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine

 tédatioxétine             4-{2-[(4-méthylphényl)sulfanyl]phényl}pipéridine

 tedatioxetina             4-{2-[(4-metilfenil)sulfanil]fenil}piperidina

                           C18H21NS




                                             S                 NH


                           H3C




 tipiracilum
 tipiracil                 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-
                           2,4-(1H,3H)-dione

 tipiracil                 5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]pyrimidine-
                           2,4-(1H,3H)-dione

 tipiracilo                5-cloro-6-[(2-iminopirrolidin-1-il)metil]pirimidina-2,4-(1H,3H)-diona

                           C9H11ClN4O2
                                             O

                                        HN        NH
                                    N
                                                       O
                           HN                Cl




326
WHO Drug Information, Vol. 26, No. 3, 2012                                               Recommended INN: List 68


 tirasemtivum
 tirasemtiv                                  6-ethynyl-1-(pentan-3-yl)-2H-imidazo[4,5-b]pyrazin-2-one

 tirasemtiv                                  6-éthynyl-1-(pentan-3-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-
                                             2-one

 tirasemtiv                                  6-etinil-1-(pentan-3-il)-2H-imidazo[4,5-b]pirazin-2-ona

                                             C12H14N4O
                                                       H3C
                                             HC                           CH3
                                                          N       N
                                                                          O
                                                          N       N
                                                                  H



 tozadenantum
 tozadenant                                  4-hydroxy-N-[4-methoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-
                                             4-methylpiperidine-1-carboxamide

 tozadénant                                  4-hydroxy-N-[4-méthoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-
                                             4-méthylpipéridine-1-carboxamide

 tozadenant                                  4-hidroxi-N-[4-metoxi-7-(morfolin-4-il)-1,3-benzotiazol-2-il]-
                                             4-metilpiperidina-1-carboxamida

                                             C19H26N4O4S

                                               O


                                                N             O
                                                                                CH3
                                                      S               N
                                                                                OH
                                                              NH
                                                      N

                                               OCH3



 trebananibum #
 trebananib                                  immunoglobulin G1 Fc fragment fused with two synthetic
                                             polypeptides that bind the Homo sapiens ANGPT2 (angiopoietin 2);
                                             methionyl (1) -gamma1 heavy chain fragment (2-228) [Homo
                                             sapiens IGHG1*01 hinge (EPKSC 1-5>del) (2-11), CH2 (12-121),
                                             CH3 (122-228)] fused, at the C-terminal end, with a synthetic
                                             polypeptide that comprises two 14-mer amino acid repeats that bind
                                             angiopoietin 2 (229-287) [linker (229-235) -14-mer (236-249) -linker
                                             (250-271) -14-mer (272-285) -leucyl-glutamate]; (7-7':10-10')-
                                             bisdisulfide dimer

 trébananib                                  immunoglobuline G1 fragment Fc fusionné à deux polypeptides
                                             synthétiques qui se lient à l'Homo sapiens ANGPT2 (angiopoïétine
                                             2);
                                             méthionyl (1) -fragment de chaîne gamma1 (2-228) [Homo sapiens
                                             IGHG1*01 charnière (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3
                                             (122-228)] fusionné, à l'extrémité C-terminale, à un polypeptide
                                             synthétique qui comprend deux motifs répétés de 14 acides aminés
                                             qui se lient à l'angiopoïétine 2 (229-287) [linker (229-235) -14-mer
                                             (236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate];
                                             dimère (7-7':10-10')-bisdisulfure



                                                                                                                 327
Recommended INN: List 68                                    WHO Drug Information, Vol. 26, No. 3, 2012




 trebananib                inmunoglobulina G1 fragmento Fc fusionado con dos polipéptidos
                           sintéticos que se unen a la ANGPT2 (angiopoyetina 2) de Homo
                           sapiens;
                           metionil (1) -fragmento de cadena gamma1 (2-228) [Homo sapiens
                           IGHG1*01 bisagra (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3
                           (122-228)] fusionada con el extremo C-terminal de un polipéptido
                           sintético que comprende dos secuencias repetidas de 14
                           aminoácidos que se unen a la angiopoyetina 2 (229-287) [conector
                           (229-235) -14-mer (236-249) -conector (250-271) -14-mer (272-285)
                           -leucil-glutamato]; dímero (7-7':10-10')-bisdisulfuro

                           MDKTHTCPPC       PAPELLGGPS      VFLFPPKPKD       TLMISRTPEV       TCVVVDVSHE        50
                           DPEVKFNWYV       DGVEVHNAKT      KPREEQYNST       YRVVSVLTVL       HQDWLNGKEY       100
                           KCKVSNKALP       APIEKTISKA      KGQPREPQVY       TLPPSRDELT       KNQVSLTCLV       150
                           KGFYPSDIAV       EWESNGQPEN      NYKTTPPVLD       SDGSFFLYSK       LTVDKSRWQQ       200
                           GNVFSCSVMH       EALHNHYTQK      SLSLSPGKGG       GGGAQQEECE       WDPWTCEHMG       250
                           SGSATGGSGS       TASSGSGSAT      HQEECEWDPW       TCEHMLE                           287

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-chain 42-102 148-206 239-246 275-282
                                        42'-102' 148'-206' 239'-246' 275'-282'
                           Inter-chains 7-7' 10-10'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           78, 78'




 trelagliptinum
 trelagliptin              2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-
                           3,4-dihydropyrimidin-1(2H)-yl}methyl)-4-fluorobenzonitrile

 trélagliptine             2-({6-[(3R)-3-aminopipéridin-1-yl]-3-méthyl-2,4-dioxo-
                           3,4-dihydropyrimidin-1(2H)-yl}méthyl)-4-fluorobenzonitrile

 trelagliptina             2-({6-[(3R)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo-
                           3,4-dihidropirimidin-1(2H)-il}metil)-4-fluorobenzonitrilo

                           C18H20FN5O2
                                 H
                           H2N

                                      N               CN

                                          N

                              O       N       O
                                      CH3             F



 umeclidinii bromidum
 umeclidinium bromide      1-{2-[(benzyl)oxy]ethyl}4-[hydroxydi(phenyl)methyl]-
                           1-azabicyclo[2.2.2]octan-1-ium bromide

 bromure d’uméclidinium    bromure de 1-{2-[(benzyl)oxy]éthyl}-4-[hydroxydi(phényl)méthyl]-
                           1-azabicyclo[2.2.2]octanium

 bromuro de umeclidinio    bromuro de 1-{2-[(bencil)oxi]etil}4-[hidroxidi(fenil)metil]-
                           1-azabiciclo[2.2.2]octan-1-io




328
WHO Drug Information, Vol. 26, No. 3, 2012                                                       Recommended INN: List 68




                                             C29H34BrNO2



                                                                        N             Br
                                                                                  O
                                                            OH




 vapendavirum
 vapendavir                                  3-ethoxy-6-{2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy}-
                                             1,2-benzoxazole

 vapendavir                                  3-éthoxy-6-{2-[1-(6-méthylpyridazin-3-yl)pipéridin-4-yl]éthoxy}-
                                             1,2-benzoxazole

 vapendavir                                  3-etoxi-6-{2-[1-(6-metilpiridazin-3-il)piperidin-4-il]etoxi}-
                                             1,2-benzoxazol

                                             C21H26N4O3

                                             H 3C       N
                                                            N                              O N
                                                                                                      CH3
                                                                                                  O
                                                                    N

                                                                                      O



 vonoprazanum
 vonoprazan                                  1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-
                                             N-methylmethanamine

 vonoprazan                                  1-[5-(2-fluorophényl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-
                                             N-méthylméthanamine

 vonoprazán                                  1-[5-(2-fluorofenil)-1-(piridina-3-sulfonil)-1H-pirrol-3-il]-
                                             N-metilmetanamina

                                             C17H16FN3O2S


                                                            O
                                                                            N
                                                        O       S
                                                                N
                                                                            CH3
                                                    F                   NH



 vortioxetinum
 vortioxetine                                1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine

 vortioxétine                                1-{2-[(2,4-diméthylphényl)sulfanyl]phényl}pipérazine

 vortioxetina                                1-{2-[(2,4-dimetilfenil)sulfanil]fenil}piperazina




                                                                                                                      329
Recommended INN: List 68                         WHO Drug Information, Vol. 26, No. 3, 2012




                           C18H22N2S



                                             N
                                       S          NH


                           H3C         CH3




330
WHO Drug Information, Vol. 26, No. 3, 2012                                                     Recommended INN: List 68




                             AMENDMENTS TO PREVIOUS LISTS
                     MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                         MODIFICACIONES A LAS LISTAS ANTERIORES


Recommended International Non Proprietary Names (Rec. INN): List 17
(Chronicle of the WHO, 1977, Vol. 31, No. 10)

p. 7           oxitropii bromidum
               oxitropium bromide       replace the description and the structure by the following ones

                                        (1R,2R,4S,5S,7s,9s)-9-ethyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-
                                                                               2,4
                                        9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0 ]nonane bromide
                                                               H
                                                                             H
                                                    O
                                                        H              CH3
                                                                   N             O Br
                                                        O
                                                 H                     CH3
                                                               H             H
                                                OH



Dénominations communes internationales recommandées (DCI Rec.): Liste 17
(Chronique de l'OMS, Vol. 31, No. 10, 1977)

p. 7           oxitropii bromidum
               bromure d’oxitropium     remplacer la description et la structure par les suivantes

                                        bromure de (1R,2R,4S,5S,7s,9s)-9-éthyl-7-{[(2S)-3-hydroxy-
                                                                                                      2,4
                                        2-phénylpropanoyl]oxy}-9-méthyl-3-oxa-9-azoniatricyclo[3.3.1.0 ]nonane
                                                               H
                                                                             H
                                                    O
                                                        H              CH3
                                                                   N             O Br
                                                        O
                                                 H                     CH3
                                                               H             H
                                                OH



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 17
(Crónica de la OMS, Vol. 31, No. 10, 1977)

p. 7           oxitropii bromidum
               bromuro de oxitropio     sustitúyase la descripción y la estructura por las siguientes

                                        bromuro de (1R,2R,4S,5S,7s,9s)-9-etil-7-{[(2S)-2-fenil-3-hidroxipropanoil]oxi}-
                                                                              2,4
                                        9-metil-3-oxa-9-azoniatriciclo[3.3.1.0 ]nonano
                                                               H
                                                                             H
                                                    O
                                                        H              CH3
                                                                   N             O Br
                                                        O
                                                 H                     CH3
                                                               H             H
                                                OH




                                                                                                                          331
Recommended INN: List 68                                                                      WHO Drug Information, Vol. 26, No. 3, 2012




Recommended International Non Proprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)



p. 260    ulipristalum
& 261     ulipristal               replace the structure by the following
          ulipristal               remplacer la structure par la suivante
          ulipristal               sustitúyase la estructura por la siguiente

                                            CH3
                                            N                                O
                                    H3C                                              CH3
                                                               H         CH3
                                                                                    OH
                                                                    H

                                                                         H
                                            O



 Recommended International Non Proprietary Names (Rec. INN): List 60
 Dénominations communes internationales recommandées (DCI Rec.): Liste 60
 Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 60
 (WHO Drug Information, Vol. 22, No. 3, 2008)


 p. 229    conestatum alfa #
           conestat alfa            replace the structure by the following
           conestat alfa            remplacer la structure par la suivante
           conestat alfa            sustitúyase la estructura por la siguiente

                                     NPNATSSSSQ         DPESLQDRGE           GKVATTVISK        MLFVEPILEV         SSLPTTNSTT            50
                                     NSATKITANT         TDEPTTQPTT           EPTTQPTIQP        TQPTTQLPTD         SPTQPTTGSF           100
                                     CPGPVTLCSD         LESHSTEAVL           GDALVDFSLK        LYHAFSAMKK         VETNMAFSPF           150
                                     SIASLLTQVL         LGAGENTKTN           LESILSYPKD        FTCVHQALKG         FTTKGVTSVS           200
                                     QIFHSPDLAI         RDTFVNASRT           LYSSSPRVLS        NNSDANLELI         NTWVAKNTNN           250
                                     KISRLLDSLP         SDTRLVLLNA           IYLSAKWKTT        FDPKKTRMEP         FHFKNSVIKV           300
                                     PMMNSKKYPV         AHFIDQTLKA           KVGQLQLSHN        LSLVILVPQN         LKHRLEDMEQ           350
                                     ALSPSVFKAI         MEKLEMSKFQ           PTLLTLPRIK        VTTSQDMLSI         MEKLEFFDFS           400
                                     YDLNLCGLTE         DPDLQVSAMQ           HQTVLELTET        GVEAAAASAI         SVARTLLVFE           450
                                     VQQPFLFVLW         DQQHKFPVFM           GRVYDPRA                                                  478

                                     Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                     101-406 108-183

                                     Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                     Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61
                                     Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-330




Recommanded International Non Proprietary Names (Rec. INN): List 61
Denominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)



p. 67     macitentanum
          macitentan               replace the chemical name by the following
                                   N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}
                                   pyrimidin-4-yl]-N'-propylsulfuric diamide



332
WHO Drug Information, Vol. 26, No. 3, 2012                                                                  Recommended INN: List 68




Recommanded International Non Proprietary Names (Rec. INN): List 62
Denominations communes internationales recommandées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 263 &   solanezumabum #
264
           solanezumab               replace the description and the structure by the following ones
           solanezumab               remplacer la description et la structure par les suivantes
           solanezumab               sustitúyase la descripción y la estructura por las siguientes

                                     immunoglobulin G1-kappa, anti-[Homo sapiens amyloid-beta (Abeta) peptide soluble
                                     monomer], humanized monoclonal antibody;
                                     gamma1 heavy chain [humanized VH (Homo sapiens IGHV3-23*04 (87.60%) -
                                     (IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens IGHG1*01 (113-442)], (215-219')-
                                     disulfide with kappa light chain (1’-219’) [humanized V-KAPPA (Homo sapiens
                                     IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-
                                     219')]; (221-221":224-224")-bisdisulfide dimer

                                     immunoglobuline G1-kappa, anti-[Homo sapiens amyloïde-bêta (Abeta) peptide
                                     monomère soluble], anticorps monoclonal humanisé;
                                     chaîne lourde gamma1 [VH humanisé (Homo sapiens IGHV3-23*04 (87.60%) -
                                     (IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens IGHG1*01 (113-442)], (215-219')-
                                     disulfure avec la chaîne légère kappa (1’-219’) [V-KAPPA humanisé (Homo sapiens
                                     IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-
                                     219')]; dimère (221-221":224-224")-bisdisulfure

                                     inmunoglobulina G1-kappa, anti-[péptido amiloide-beta (Abeta) monomèrico soluble
                                     de Homo sapiens], anticuerpo monoclonal humanizado;
                                     cadena pesada gamma1 [VH humanizado (Homo sapiens IGHV3-23*04 (87.60%) -
                                     (IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens IGHG1*01 (113-442)], (215-219')-
                                     disulfuro con la cadena ligera kappa (1’-219’) [V-KAPPA humanizado (Homo
                                     sapiens IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                                     IGKC*01 (113'-219')]; dímero (221-221":224-224")-bisdisulfuro

                                     Heavy chain / Chaîne lourde / Cadena pesada
                                     EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  RYSMSWVRQA       PGKGLELVAQ        50
                                     INSVGNSTYY PDTVKGRFTI SRDNAKNTLY                  LQMNSLRAED       TAVYYCASGD       100
                                     YWGQGTLVTV SSASTKGPSV FPLAPSSKST                  SGGTAALGCL       VKDYFPEPVT       150
                                     VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV                  VTVPSSSLGT       QTYICNVNHK       200
                                     PSNTKVDKKV EPKSCDKTHT CPPCPAPELL                  GGPSVFLFPP       KPKDTLMISR       250
                                     TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH                  NAKTKPREEQ       YNSTYRVVSV       300
                                     LTVLHQDWLN GKEYKCKVSN KALPAPIEKT                  ISKAKGQPRE       PQVYTLPPSR       350
                                     DELTKNQVSL TCLVKGFYPS DIAVEWESNG                  QPENNYKTTP       PVLDSDGSFF       400
                                     LYSKLTVDKS RWQQGNVFSC SVMHEALHNH                  YTQKSLSLSP       GK               442

                                     Light chain / Chaîne légère / Cadena ligera
                                     DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI                  YSDGNAYLHW       FLQKPGQSPR 50
                                     LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCSQSTHVP 100
                                     WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                     VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                     VTHQGLSSPV TKSFNRGEC                                                          219

                                     Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                     Intra-H 22-96        139-195       256-316  362-420
                                              22''-96'' 139''-195'' 256''-316'' 362''-420''
                                     Intra-L 23'-93'      139'-199'
                                              23'''-93''' 139'''-199'''
                                     Inter-H-L 215-219' 215''-219'''
                                     Inter-H-H 221-221'' 224-224''

                                     N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                     H VH CDR2-IMGT N63:
                                     56, 56''
                                     H CH2 N84.4:
                                     292, 292''



                                                                                                                                       333
Recommended INN: List 68                                                              WHO Drug Information, Vol. 26, No. 3, 2012


Recommended International Non Proprietary Names (Rec. INN): List 64
Dénominations communes internationales recommandées (DCI Rec.): Liste 64
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64
(WHO Drug Information, Vol. 23, No. 4, 2009)

p. 264 &   dalotuzumabum #
265
           dalotuzumab            replace the description and the structure by the following ones
           dalotuzumab            remplacer la description et la structure par les suivantes
           dalotuzumab            sustitúyase la descripción y la estructura por las siguientes

                                  immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like growth factor 1
                                  receptor, IGF1-R, IGF-1R, CD221], humanized monoclonal antibody;
                                  gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV4-61*08
                                  (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03 (118-
                                  447)], (220-219')-disulfide with kappa light chain (1’-219’) [humanized V-KAPPA
                                  (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo
                                  sapiens IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer

                                  immunoglobuline G1-kappa, anti-[Homo sapiens IGF1R (récepteur du facteur
                                  de croissance 1 analogue à l’insuline (IGF1-R, IGF-1R, CD221)], anticorps
                                  monoclonal humanisé;
                                  chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV4-61*08
                                  (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03 (118-
                                  447)], (220-219')-disulfure avec la chaîne légère kappa (1’-219’) [V-KAPPA
                                  humanisé (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112')
                                  -Homo sapiens IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure

                                  inmunoglobulina G1-kappa, anti-[Homo sapiens IGF1R (receptor del factor de
                                  crecimiento similar a la insulina 1 (IGF1-R, IGF-1R, CD221)], anticuerpo
                                  monoclonal humanizado;
                                  cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV4-61*08
                                  (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03 (118-
                                  447)], (220-219')-disulfuro con la cadena ligera kappa (1’-219’) [V-KAPPA
                                  humanizado (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -
                                  Homo sapiens IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro

                                   Heavy chain / Chaîne lourde / Cadena pesada
                                   QVQLQESGPG LVKPSETLSL TCTVSGYSIT                  GGYLWNWIRQ       PPGKGLEWIG        50
                                   YISYDGTNNY KPSLKDRVTI SRDTSKNQFS                  LKLSSVTAAD       TAVYYCARYG       100
                                   RVFFDYWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                                   PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                                   NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                                   LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                                   RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                                   LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                   DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                                   Light chain / Chaîne légère / Cadena ligera
                                   DIVMTQSPLS LPVTPGEPAS ISCRSSQSIV                  HSNGNTYLQW       YLQKPGQSPQ 50
                                   LLIYKVSNRL YGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCFQGSHVP 100
                                   WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                   VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                   VTHQGLSSPV TKSFNRGEC                                                          219

                                   Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                   Intra-H 22-96        144-200       261-321  367-425
                                            22''-96'' 144''-200'' 261''-321'' 367''-425''
                                   Intra-L 23'-93'       139'-199'
                                            23'''-93''' 139'''-199'''
                                   Inter-H-L 220-219' 220''-219'''
                                   Inter-H-H 226-226'' 229-229''

                                   N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                   H CH2 N84.4
                                   297, 297''




334
WHO Drug Information, Vol. 26, No. 3, 2012                                                           Recommended INN: List 68




Recommended International Non Proprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)



p. 70     lipegfilgrastimum #
          lipegfilgrastim          replace the description and the structure by the following ones
          lipegfilgrastim          remplacer la description et la structure par les suivantes
          lipegfilgrastim          sustitúyase la descripción y la estructura por las siguientes

                                   pegylated granulocyte colony stimulating factor (human short isoform);
                                     3.137
                                   O      -[{3,5-dideoxy-5-[(N-{[ω-methoxypoly(oxyethylene)]carbonyl}glycyl)amino]-
                                   D-glycero-α-D-galacto-non-2-ulopyranosylonic acid}-(2→6)-2-(acetylamino)-2-deoxy-
                                   α-D-galactopyranosyl]-des-(37-39)-[1-methionine]human granulocyte
                                   colony-stimulating factor (G-CSF, pluripoietin)

                                   facteur de stimulation de colonie de granulocytes (isoforme court humain) pégylé;
                                     3.137
                                    O     -[{acide 3,5-didéoxy-5-[(N-{[ω-méthoxypoly(oxyéthylène)]carbonyl}glycyl)amino]-
                                   D-glycéro-α-D-galacto-non-2-ulopyranosylonique}-(2→6)-2-(acétylamino)-2-déoxy-
                                   α-D-galactopyranosyl]-dès-(37-39)-[1-méthionine]facteur humain de stimulation de
                                   colonie de granulocytes (G-CSF, pluripoïétine)

                                   factor de estimulacin de colonías de granulocitos (isoformo corto humano) pegilado;
                                     3.137
                                   O      -[{acído 3,5-didesoxi-5-[(N-{[ω-metoxipoli(oxietileni)]carbonil}glicil)amino]-
                                   D-glicero-α-D-galacto-non-2-ulopiranosilonico}-(2→6)-2-(acetilamino)-2-desoxi-
                                   α-D-galactopiranosil]-dès-(37-39)-[1-metionina]factor humano de estimulación de
                                   colonías de granulocitos (G-CSF, pluripoyetina)

                                    MTPLGPASSL      PQSFLLKCLE       QVRKIQGDGA ALQEKL---C ATYKLCHPEE 50
                                    LVLLGHSLGI      PWAPLSSCPS       QALQLAGCLS QLHSGLFLYQ GLLQALEGIS 100
                                    PELGPTLDTL      QLDVADFATT       IWQQMEELGM APALQPTQGA MPAFASAFQR 150
                                    RAGGVLVASH      LQSFLEVSYR       VLRHLAQP                         178

                                    Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                    40-46 68-78

                                    Modified residues / Résidu modifié / Residuo modificado
                                                                              HO           OH
                                                                                                    CO2H
                                              T                                                O
                                                                                   HO H              O
                                             137
                                    PEG-Gly-Neu-GalNac-Thr                                                        O                CH3
                                                                                      HN            HO                     O        H
                                                                                  H
                                                          H3C             O       N            OH
                                                                O                          O                                H2 N     CO2H
                                                                          n                              HO           NH
                                                                              O
                                                                                                              O
                                                                                                                      CH3




                                                                                                                                         335
 Recommended INN: List 68                                                WHO Drug Information, Vol. 26, No. 3, 2012




 # Electronic structure available on Mednet: http://mednet.who.int/
 # Structure électronique disponible sur Mednet: http://mednet.who.int/
 # Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 336
